220 related articles for article (PubMed ID: 36344500)
1. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response.
Baldwin LA; Bartonicek N; Yang J; Wu SZ; Deng N; Roden DL; Chan CL; Al-Eryani G; Zanker DJ; Parker BS; Swarbrick A; Junankar S
Nat Commun; 2022 Nov; 13(1):6539. PubMed ID: 36344500
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.
Gutwillig A; Santana-Magal N; Farhat-Younis L; Rasoulouniriana D; Madi A; Luxenburg C; Cohen J; Padmanabhan K; Shomron N; Shapira G; Gleiberman A; Parikh R; Levy C; Feinmesser M; Hershkovitz D; Zemser-Werner V; Zlotnik O; Kroon S; Hardt WD; Debets R; Reticker-Flynn NE; Rider P; Carmi Y
Elife; 2022 Sep; 11():. PubMed ID: 36124553
[TBL] [Abstract][Full Text] [Related]
4. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunoediting and resistance to T cell-based immunotherapy.
O'Donnell JS; Teng MWL; Smyth MJ
Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunoediting in the Era of Immuno-oncology.
Gubin MM; Vesely MD
Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
[TBL] [Abstract][Full Text] [Related]
10. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution.
Wu T; Wang G; Wang X; Wang S; Zhao X; Wu C; Ning W; Tao Z; Chen F; Liu XS
Cancer Res; 2022 Jun; 82(12):2226-2238. PubMed ID: 35486454
[TBL] [Abstract][Full Text] [Related]
11. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells.
Nguyen LV; Pellacani D; Lefort S; Kannan N; Osako T; Makarem M; Cox CL; Kennedy W; Beer P; Carles A; Moksa M; Bilenky M; Balani S; Babovic S; Sun I; Rosin M; Aparicio S; Hirst M; Eaves CJ
Nature; 2015 Dec; 528(7581):267-71. PubMed ID: 26633636
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
[TBL] [Abstract][Full Text] [Related]
13. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
[TBL] [Abstract][Full Text] [Related]
14. Detection of chemotherapy-resistant patient-derived acute lymphoblastic leukemia clones in murine xenografts using cellular barcodes.
Jacobs S; Ausema A; Zwart E; Weersing E; de Haan G; Bystrykh LV; Belderbos ME
Exp Hematol; 2020 Nov; 91():46-54. PubMed ID: 32946982
[TBL] [Abstract][Full Text] [Related]
15. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Chen IX; Chauhan VP; Posada J; Ng MR; Wu MW; Adstamongkonkul P; Huang P; Lindeman N; Langer R; Jain RK
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4558-4566. PubMed ID: 30700545
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
17. New Strategies in Breast Cancer: Immunotherapy.
Pusztai L; Karn T; Safonov A; Abu-Khalaf MM; Bianchini G
Clin Cancer Res; 2016 May; 22(9):2105-10. PubMed ID: 26867935
[TBL] [Abstract][Full Text] [Related]
18. Immunological barriers to immunotherapy in primary and metastatic breast cancer.
De Martino M; Vanpouille-Box C; Galluzzi L
EMBO Mol Med; 2021 Aug; 13(8):e14393. PubMed ID: 34128586
[TBL] [Abstract][Full Text] [Related]
19. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
Matsushita H; Vesely MD; Koboldt DC; Rickert CG; Uppaluri R; Magrini VJ; Arthur CD; White JM; Chen YS; Shea LK; Hundal J; Wendl MC; Demeter R; Wylie T; Allison JP; Smyth MJ; Old LJ; Mardis ER; Schreiber RD
Nature; 2012 Feb; 482(7385):400-4. PubMed ID: 22318521
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
Eirew P; Steif A; Khattra J; Ha G; Yap D; Farahani H; Gelmon K; Chia S; Mar C; Wan A; Laks E; Biele J; Shumansky K; Rosner J; McPherson A; Nielsen C; Roth AJ; Lefebvre C; Bashashati A; de Souza C; Siu C; Aniba R; Brimhall J; Oloumi A; Osako T; Bruna A; Sandoval JL; Algara T; Greenwood W; Leung K; Cheng H; Xue H; Wang Y; Lin D; Mungall AJ; Moore R; Zhao Y; Lorette J; Nguyen L; Huntsman D; Eaves CJ; Hansen C; Marra MA; Caldas C; Shah SP; Aparicio S
Nature; 2015 Feb; 518(7539):422-6. PubMed ID: 25470049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
